Nationwide oncological networks for resection of colorectal liver metastases in the Netherlands: Differences and postoperative outcomes.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
Feb 2022
Historique:
received: 09 04 2021
revised: 29 08 2021
accepted: 02 09 2021
pubmed: 22 11 2021
medline: 8 3 2022
entrez: 21 11 2021
Statut: ppublish

Résumé

Widespread differences in patient demographics and disease burden between hospitals for resection of colorectal liver metastases (CRLM) have been described. In the Netherlands, networks consisting of at least one tertiary referral centre and several regional hospitals have been established to optimize treatment and outcomes. The aim of this study was to assess variation in case-mix, and outcomes between these networks. This was a population-based study including all patients who underwent CRLM resection in the Netherlands between 2014 and 2019. Variation in case-mix and outcomes between seven networks covering the whole country was evaluated. Differences in case-mix, expected 30-day major morbidity (Clavien-Dindo ≥3a) and 30-day mortality between networks were assessed. In total 5383 patients were included. Thirty-day major morbidity was 5.7% and 30-day mortality was 1.5%. Significant differences between networks were observed for Charlson Comorbidity Index, ASA 3+, previous liver resection, liver disease, preoperative MRI, preoperative chemotherapy, ≥3 CRLM, diameter of largest CRLM ≥55 mm, major resection, combined resection and ablation, rectal primary tumour, bilobar and extrahepatic disease. Uncorrected 30-day major morbidity ranged between 3.3% and 13.1% for hospitals, 30-day mortality ranged between 0.0% and 4.5%. Uncorrected 30-day major morbidity ranged between 4.4% and 6.0% for networks, 30-day mortality ranged between 0.0% and 2.5%. No negative outliers were observed after case-mix correction. Variation in case-mix and outcomes are considerably smaller on a network level as compared to a hospital level. Therefore, auditing is more meaningful at a network level and collaboration of hospitals within networks should be pursued.

Identifiants

pubmed: 34801321
pii: S0748-7983(21)00727-7
doi: 10.1016/j.ejso.2021.09.004
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

435-448

Investigateurs

Cornelis H C Dejong (CHC)
Marc G H Besselink (MGH)
Marieke T de Boer (MT)
Andries E Braat (AE)
Jeroen Hagendoorn (J)
Frederik J H Hoogwater (FJH)
I Quintus Molenaar (IQ)

Informations de copyright

Copyright © 2021. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Arthur K E Elfrink (AKE)

Dutch Institute for Clinical Auditing, Scientific Bureau, Leiden, the Netherlands; Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands. Electronic address: elfrinkake@gmail.com.

Niels F M Kok (NFM)

Department of Surgery, Antoni van Leeuwenhoek - Dutch Cancer Institute, Amsterdam, the Netherlands.

Rutger-Jan Swijnenburg (RJ)

Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Marcel den Dulk (M)

Department of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands.

Peter B van den Boezem (PB)

Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.

Henk H Hartgrink (HH)

Department of Surgery, Radboud Medical Center, Nijmegen, the Netherlands.

Wouter W Te Riele (WW)

Department of Surgery, University Medical Center Utrecht, Utrecht, the Netherlands; Department of Surgery, St. Antonius Hospital, Nieuwegein, the Netherlands.

Gijs A Patijn (GA)

Department of Surgery, Isala, Zwolle, the Netherlands.

Wouter K G Leclercq (WKG)

Department of Surgery, Máxima Medical Center, Veldhoven, the Netherlands.

Daan J Lips (DJ)

Department of Surgery, Medisch Spectrum Twente, Enschede, the Netherlands.

Ninos Ayez (N)

Department of Surgery, Amphia Medical Center, Breda, the Netherlands.

Cornelis Verhoef (C)

Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Koert F D Kuhlmann (KFD)

Department of Surgery, Antoni van Leeuwenhoek - Dutch Cancer Institute, Amsterdam, the Netherlands.

Carlijn I Buis (CI)

Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands.

Koop Bosscha (K)

Department of Surgery, Jeroen Bosch Ziekenhuis, 's Hertogenbosch, the Netherlands.

Eric J T Belt (EJT)

Department of Surgery, Albert Schweitzer Hospital, Dordrecht, the Netherlands.

Maarten Vermaas (M)

Department of Surgery, Ijsselland Hospital, Capelle a/d Ijssel, the Netherlands.

N Tjarda van Heek (NT)

Department of Surgery, Gelderse Vallei, Ede, the Netherlands.

Steven J Oosterling (SJ)

Department of Surgery, Spaarne Gasthuis, Hoofddorp, the Netherlands.

Hans Torrenga (H)

Department of Surgery, Deventer Hospital, Deventer, the Netherlands.

Hasan H Eker (HH)

Department of Surgery, Medical Centre Leeuwarden, Leeuwarden, the Netherlands.

Esther C J Consten (ECJ)

Department of Surgery, Meander Medical Centre, Amersfoort, the Netherlands.

Hendrik A Marsman (HA)

Department of Surgery, OLVG, Amsterdam, the Netherlands.

Geert Kazemier (G)

Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands.

Michel W J M Wouters (MWJM)

Dutch Institute for Clinical Auditing, Scientific Bureau, Leiden, the Netherlands; Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, the Netherlands.

Dirk J Grünhagen (DJ)

Department of Surgery, Antoni van Leeuwenhoek - Dutch Cancer Institute, Amsterdam, the Netherlands.

Joost M Klaase (JM)

Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH